Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

Mark G Lebwohl; Jeffrey L Sugarman; Linda Stein Gold; Tina Lin; Gina Martin

doi:10.25251/skin.3.supp.29

Mark G Lebwohl

Icahn School of Medicine at Mount Sinai, New York, NY

Jeffrey L Sugarman

University of California, San Francisco, CA

Linda Stein Gold

Henry Ford Hospital, Detroit, MI

Tina Lin

Ortho Dermatologics, Bridgewater, NJ

Gina Martin

Bausch Health Americas, Inc, Petaluma, CA

Keywords

psoriasis, tazarotene, halobetasol

Abstract

Abstract not available.

References

1. Nestle FO, et al. N Engl J Med. 2009;361(5):496-509.

2. Cohen SN, et al. Clin Exp Dermatol. 2012;37 Suppl 1:13-18.

3. Menter A, et al. J Am Acad Dermatol. 2009;60(4):643-659.

4. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855-861.

Poster PDF

Published

Nov 9, 2019

DOI https://doi.org/10.25251/skin.3.supp.29

How to Cite

Lebwohl, M. G., Sugarman, J. L., Gold, L. S., Lin, T., & Martin, G. (2019). Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. SKIN The Journal of Cutaneous Medicine, 3, S29. https://doi.org/10.25251/skin.3.supp.29

Issue

Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Linda Stein Gold, James Q Del Rosso, Neal D Bhatia, et al., Efficacy and Safety of FMX103 (1.5% Minocycline Foam) in the Treatment of Moderate to Severe Papulopustular Rosacea: Results from two Phase 3 Randomized, Multicenter, Double Blind, Vehicle Controlled Studies , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, Michelle Pelle, Bradley Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Kevin Douglas, Greg St. John, Ramon Espaillat, Robert Bissonnette, A Phase 3b Study Evaluating Safety and Efficacy of Risankizumab in Adult Patients with Moderate-to-Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Linda Stein Gold, Sunhil Dhawan, Jonathan Weiss, Zoe Diana Draelos, Herman Ellman, Iain Stuart, An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Zoe Draelos, Fran Cook-Bolden, Lawrence Green, Eric Guenin, Gina Martin, Radhakrishnan Pillai, Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Jonathan I. Silverberg, Lawrence F. Eichenfield, Adelaide A. Hebert, Eric Simpson, Linda Stein Gold, Robert Bissonnette, Kim A. Papp, John Browning, Pearl Kwong, Neil J. Korman, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Matthew C. Somerville, Anna Tallman, Leon Kircik, Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Lina Stein Gold, Mark G Lebwohl, Neal Bhatia, Tina Lin, Radhakrishnan Pillai, Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Emil A Tanghetti, Linda Stein Gold, James Q Del Rosso, Stefan Weiss, Tina Lin, Arturo Angel, Radhakrishnan Pillai, Optimized Formulation for Topical Application of a Fixed Combination Halobetasol/Tazarotene Lotion Using Polymeric Emulsion Technology , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Linda Stein Gold, Joshua Zeichner, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi, DFD 29, a low dose oral minocycline, shows significant improvement in quality of life in subjects with papulopustular rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Eric Simpson, Jonathan I. Silverberg, Robert Bissonnette, Linda Stein Gold, April Armstrong, Adelaide A. Hebert, Rocco T. Serrao, Jeannette R. Jakus, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Anna Tallman, Lawrence F. Eichenfield, Rapid and Early Onset of Itch Relief with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to Two Years of Age with Atopic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Julie C Harper, Hilary E Baldwin, Saswata Paul Choudhury, Bikramaditya Ghosh, Deepti Rai, Md Sohail Aman, Abhra Roy Choudhury, Debalina Dey , Sekhar K Dutta, Subrata Bhattacharyya, Tina Lin, George Joseph, Ankur A Dashputre, Jerry Tan, A Systematic Literature Review and Network Meta-Analysis of Comparative Efficacy of Topical Fixed-Dose Combination Treatments for Moderate to Severe Acne Vulgaris , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue

<< < 1 2 3 4 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)